TaiGen Biotechnology Co (太景生技) is confident its can meet increasingly stringent requirements for new drug approvals in China, after it became the first Taiwanese firm to receive regulatory approval for its non-fluorinated quinolone antibacterial drug, Taigexyn, in Taiwan and China last month.
The Chinese Food and Drug Administration (CFDA) gave Taigexyn a class 1.1 designation, due to its indications for community-borne pneumonia and infections caused by diabetic foot ulcers.
CROSS-STRAIT PRECEDENT
“A precedent for new drug approvals in cross-strait collaborations in the biotechnology field has been set by Taigexyn,” TaiGen chairman and chief operating officer Hsu Ming-chu (許明珠) said at a BioTaiwan Exhibition forum yesterday.
Three more products are on track to be approved by the CFDA, thanks to what it has learned, Hsu said.
Hsu said that the company has seen a change in the CFDA throughout its decade-long efforts for CFDA approval, and that the process began to speed up 2012, six years after it established a level of trust and communication with the regulator.
During that time, the company began benefiting from bilateral agreements between food and drug regulators in Taiwan and China to cut down on redundant clinical trial requirements, with authorities now recognizing clinical study data conducted in both nations, Hsu said, adding that Taiwanese and Chinese share a very similar genetic makeup.
However, China had elevated its data assessment requirements significantly during the same period, she said.
SHIFT FROM GENERIC
Facing immense healthcare and medical expenses in China, the CFDA has shifted its focus from generic drugs to new drugs development, leading to more stringent regulatory requirements, Hsu said.
China’s change was driven by its goal to better control national healthcare costs by expanding domestic development and reducing reliance on imported products, Hsu said.
In 2014, the CFDA announced stricter data requirements for more than 2,000 New Drug Applications that were awaiting assessment and companies were advised to ensure that their data was valid.
UNABLE TO ADJUST
Consequently, all but about 200 companies, including TaiGen, retracted their applications, she said, adding that many companies were unable to adjust to the new standards.
In addition, TaiGen faced a 24-member review committee for Taigexyn, which Hsu said was significantly more strenuous than compared with US regulators.
In terms of competition in antibiotics of Taigexyn class, Beyer’s Avelox recorded sales of 1.6 billion yuan (US$239.75 million), while Lai Li Xin, which is sold by Zhejiang Medicine Co (浙江醫藥), TaiGen’s partner in China, posted sales of 1.03 billion yuan.
China’s total market for antibiotics is estimated at 79.7 billion yuan, Hsu said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained